Vevorisertib

Vevorisertib (ARQ 751) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations.
Read more
€0.00 (tax incl.)
Reference:
HY-137458
Product Details
HY-137458

Data sheet

Size
Multiple sizes
Reactivity
Akt; Ser/Thr Protease
Application
Cancer-Kinase/protease
CAS
1416775-46-6

Menu

Settings